Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Investment analysts at Zacks Research issued their Q1 2025 EPS estimates for shares of Amicus Therapeutics in a research report issued on Tuesday, April 1st. Zacks Research analyst R. Department anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' Q3 2026 earnings at $0.11 EPS.
A number of other brokerages have also recently issued reports on FOLD. Morgan Stanley reissued an "equal weight" rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company decreased their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.
View Our Latest Stock Analysis on FOLD
Amicus Therapeutics Stock Performance
Shares of NASDAQ:FOLD traded down $0.37 during trading on Thursday, hitting $7.14. 2,674,323 shares of the company were exchanged, compared to its average volume of 2,536,543. The company has a market cap of $2.19 billion, a PE ratio of -39.54, a P/E/G ratio of 1.51 and a beta of 0.79. Amicus Therapeutics has a 52-week low of $6.99 and a 52-week high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock has a 50 day moving average of $9.12 and a 200 day moving average of $9.84.
Hedge Funds Weigh In On Amicus Therapeutics
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after buying an additional 458,143 shares during the last quarter. Wellington Management Group LLP increased its stake in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares during the period. Geode Capital Management LLC lifted its position in Amicus Therapeutics by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company's stock valued at $70,499,000 after purchasing an additional 80,926 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Amicus Therapeutics by 4.4% during the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after purchasing an additional 159,139 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Amicus Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock worth $31,761,000 after purchasing an additional 187,652 shares during the last quarter.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Recommended Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
